TPWA
GALT icon

TRUE Private Wealth Advisors’s Galectin Therapeutics GALT Stock Holding History

TRUE Private Wealth Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$2K – 418
2020
Q4 		$2K Hold
1,000
– – ﹤0.01% 661
2020
Q3 		$2K Buy
+1,000
New +$2.8K ﹤0.01% 623

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

TRUE Private Wealth Advisors's GALT Position: Q1 2021 in Review

TRUE Private Wealth Advisors sold out of Galectin Therapeutics (GALT) in Q1 2021, closing a stake of 1,000 shares — an estimated $2K sold.

TRUE Private Wealth Advisors first reported a position in GALT in Q3 2020 and held it in 2 quarters. The position peaked at $2K in Q4 2020. 75 funds tracked by Wall St. Rank hold GALT as of Q1 2021.

  • TRUE Private Wealth Advisors reported no remaining Galectin Therapeutics position as of Q1 2021 after selling out during the quarter.
  • TRUE Private Wealth Advisors sold 1,000 Galectin Therapeutics shares in Q1 2021, an estimated $2K.
  • TRUE Private Wealth Advisors first reported a position in Galectin Therapeutics in Q3 2020 and held it in 2 quarters.
  • TRUE Private Wealth Advisors's Galectin Therapeutics position peaked at $2K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2021.

Based on TRUE Private Wealth Advisors's 13F filing for Q1 2021, filed 12 May 2021.